Empagliflozin as monotherapy or add-on therapy in South Asian patients with Type 2 diabetes: post hoc analysis of pooled data from four phase III trials

被引：0
|
作者：
Khunti, K. [1 ]
Asaro-Harris, A. [2 ]
Spencer, W. [3 ]
Pfarr, E. [4 ]
Naderali, E. [2 ]
Salsali, A. [5 ]
Hach, T. [4 ]
机构：
[1] Univ Leicester, Leicester, Leics, England
[2] Eli Lilly & Co, Basingstoke, Hants, England
[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P217
引用
收藏
页码：96 / 97
页数：2
相关论文
共 50 条
  • [21] Safety and tolerability of atogepant: a post hoc analysis of pooled data from four clinical trials
    Rizzoli, P.
    Marmura, M.
    Robblee, J.
    McVige, J.
    Sacco, S.
    Ferreira, R. De Abreu
    Rekeda, L.
    Ma, J.
    Dabruzzo, B.
    Ashina, M.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [22] The Efficacy and Safety of Imeglimin as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
    Fouqueray, Pascale
    Pirags, Valdis
    Inzucchi, Silvio
    Bailey, Clifford J.
    Schernthaner, Guntram
    Diamant, Michaela
    Lebovitz, Harold E.
    DIABETES, 2012, 61 : A257 - A257
  • [23] Efficacy and safety of exenatide once weekly in patients with type 2 diabetes mellitus: a post hoc analysis of pooled data from the DURATION clinical trials
    Ruggles, J.
    Grimm, M.
    Han, J.
    Weaver, C.
    Griffin, P.
    Schulteis, C.
    Dong, H.
    Maggs, D.
    Malloy, J.
    DIABETOLOGIA, 2012, 55 : S329 - S329
  • [24] Impact of Empagliflozin Add-on Therapy on Quality of Life in Patients of Type 2 Diabetes Mellitus with Hypertension: A Prospective Study
    Najar, Imtiyaz
    Masoodi, Shariq
    Mir, Shakeel
    Bhat, Moomin
    Patyar, Rakesh
    Patyar, Sazal
    INDIAN JOURNAL OF PUBLIC HEALTH, 2022, 66 (05) : 41 - 44
  • [25] The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
    Fouqueray, Pascale
    Pirags, Valdis
    Inzucchi, Silvio E.
    Bailey, Clifford J.
    Schernthaner, Guntram
    Diamant, Michaela
    Lebovitz, Harold E.
    DIABETES CARE, 2013, 36 (03) : 565 - 568
  • [26] The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy
    Fouqueray, Pascale
    Pirags, Valdis
    Diamant, Michaela
    Schernthaner, Guntram
    Lebovitz, Harold E.
    Inzucchi, Silvio E.
    Bailey, Clifford J.
    DIABETES CARE, 2014, 37 (07) : 1924 - 1930
  • [27] Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials
    Watada, Hirotaka
    Yamauchi, Toshimasa
    Yamamoto, Fumiko
    Taniguchi, Atsushi
    Yarush, Larisa
    Heilmann, Clemens
    Yasui, Atsutaka
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (09) : 1193 - 1202
  • [28] Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus
    Jawed, Bilal
    Ahmed, Shadab
    Abbas, Syed Qamar
    Ahmed, Zeeshan
    Andleeb, Shomaiza
    Ahmad, Salman Ashfaq
    Asif, Muhammad
    Akhter, Erum
    Ahmed, Salman
    Hussain, Muhammad Waleed
    Iqbal, Adnan
    Ishaqui, Azfar Athar
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 35 (06) : 1733 - 1738
  • [29] Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp
    Yang, Wenying
    Akhtar, Shahid
    Franek, Edward
    Haluzik, Martin
    Hirose, Takahisa
    Kalyanam, Balamurali
    Kar, Soumitra
    Wu, Ted
    Yavuz, Dilek Gogas
    Unnikrishnan, Ambika Gopalakrishnan
    DIABETES THERAPY, 2022, 13 (02) : 311 - 323
  • [30] Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp
    Wenying Yang
    Shahid Akhtar
    Edward Franek
    Martin Haluzík
    Takahisa Hirose
    Balamurali Kalyanam
    Soumitra Kar
    Ted Wu
    Dilek Gogas Yavuz
    Ambika Gopalakrishnan Unnikrishnan
    Diabetes Therapy, 2022, 13 : 311 - 323
12345